Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KN046 + axitinib
- Development stage
- Unknown
- Lead developer
- AlphaMab Oncology
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
KN046 + axitinib is a combination therapy being investigated for the treatment of advanced non-small cell lung cancer (NSCLC). This combination pairs KN046, a bispecific antibody targeting both PD-L1 and CTLA-4 immune checkpoints, with axitinib, a tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR). By combining these two mechanisms, the therapy aims to enhance anti-tumor activity through both immune activation and anti-angiogenic effects.
- Brand names
- Inlyta
- Other names
- KN046 plus AxitinibKN-046 plus AxitinibKN 046 plus Axitinib
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRB (Platelet-derived growth factor receptor beta)FGFR3 (Fibroblast growth factor receptor 3)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)TEK (Tie2)VEGFR-1 (Vascular endothelial growth factor receptor 1)CD274 (Programmed cell death protein 1 ligand 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on KN046 + axitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KN046 + axitinib.